Eosinophilic esophagitis: an autoimmune esophageal disorder
- PMID: 25499460
- DOI: 10.1016/j.cppeds.2014.10.004
Eosinophilic esophagitis: an autoimmune esophageal disorder
Abstract
Eosinophilic esophagitis (EoE) represents a chronic, immune/antigen-mediated esophageal inflammatory disease associated with esophageal dysfunction resulting from severe inflammation. The incidence and prevalence of EoE have been increasing in the past decade; however, the reason for this increase is unclear. There is a chronic inflammatory infiltrate that is present in EoE which promotes inflammation, symptoms, and dysfunction. In addition to eosinophils, interleukin (IL)-5 expressing T cells, B cells, eotaxin-3, IL-13, and IgE-bearing mast cells are present in EoE and are thought to contribute to the disease process. Eosinophils are pro-inflammatory and modulate multiple aspects of the immune response. Eosinophils produce a wide range of inflammatory cytokines, chemokines, granulocyte-monocyte colony-stimulating factors, and tumor necrosis factors. Once activated, eosinophils release granule components, which are toxic to a variety of tissues. Transforming growth factor β1 is a pro-fibrotic molecule produced by epithelial and inflammatory cells, is overexpressed in EoE, and plays a role in esophageal remodeling. Fibrous remodeling in EoE could be associated with symptoms of dysphagia and may explain and predict future esophageal strictures and dysmotility. EoE is a complex disease involving multiple activation pathways, a large number of cells, and various inflammatory molecules. It, along with other atopic disease, is becoming increasingly prevalent and has an important genetic load and may represent as an immunological tolerance disorder of the GI tract.
Copyright © 2014 Mosby, Inc. All rights reserved.
Similar articles
-
Cellular and molecular immunological mechanisms in eosinophilic esophagitis: an updated overview of their clinical implications.Expert Rev Gastroenterol Hepatol. 2014 Aug;8(6):669-85. doi: 10.1586/17474124.2014.909727. Epub 2014 Apr 18. Expert Rev Gastroenterol Hepatol. 2014. PMID: 24742298 Review.
-
Biological Therapies for Eosinophilic Esophagitis: Where Do We Stand?Clin Rev Allergy Immunol. 2018 Oct;55(2):205-216. doi: 10.1007/s12016-018-8674-3. Clin Rev Allergy Immunol. 2018. PMID: 29372536 Review.
-
Molecular basis and cellular mechanisms of eosinophilic esophagitis for the clinical practice.Expert Rev Gastroenterol Hepatol. 2019 Feb;13(2):99-117. doi: 10.1080/17474124.2019.1546120. Epub 2018 Nov 15. Expert Rev Gastroenterol Hepatol. 2019. PMID: 30791784 Review.
-
Targeting granulocyte-macrophage colony-stimulating factor in epithelial and vascular remodeling in experimental eosinophilic esophagitis.Allergy. 2017 Aug;72(8):1232-1242. doi: 10.1111/all.13105. Epub 2017 Jan 23. Allergy. 2017. PMID: 27926989
-
Tissue remodeling in eosinophilic esophagitis.Am J Physiol Gastrointest Liver Physiol. 2012 Dec 1;303(11):G1175-87. doi: 10.1152/ajpgi.00313.2012. Epub 2012 Sep 27. Am J Physiol Gastrointest Liver Physiol. 2012. PMID: 23019192 Free PMC article. Review.
Cited by
-
Temporal Regulation by Innate Type 2 Cytokines in Food Allergies.Curr Allergy Asthma Rep. 2016 Oct;16(10):75. doi: 10.1007/s11882-016-0656-z. Curr Allergy Asthma Rep. 2016. PMID: 27771884 Review.
-
Eosinophilic esophagitis in adults: An update.World J Gastrointest Pharmacol Ther. 2016 May 6;7(2):207-13. doi: 10.4292/wjgpt.v7.i2.207. World J Gastrointest Pharmacol Ther. 2016. PMID: 27158535 Free PMC article. Review.
-
Vasoactive Intestinal Peptide Receptor, CRTH2, Antagonist Treatment Improves Eosinophil and Mast Cell-Mediated Esophageal Remodeling and Motility Dysfunction in Eosinophilic Esophagitis.Cells. 2024 Feb 6;13(4):295. doi: 10.3390/cells13040295. Cells. 2024. PMID: 38391908 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous